Literature DB >> 20423337

Isoflurane protects cardiomyocytes and mitochondria by immediate and cytosol-independent action at reperfusion.

D Pravdic1, Y Mio, F Sedlic, P F Pratt, D C Warltier, Z J Bosnjak, M Bienengraeber.   

Abstract

BACKGROUND AND
PURPOSE: The volatile anaesthetic isoflurane protects the heart from ischaemia and reperfusion (I/R) injury when applied at the onset of reperfusion [anaesthetic postconditioning (APoC)]. However, the mechanism of APoC-mediated protection is unknown. In this study, we examined the effect of APoC on mitochondrial bioenergetics, mitochondrial matrix pH (pH(m)) and cytosolic pH (pH(i)), and intracellular Ca(2+). EXPERIMENTAL APPROACH: Cardiac mitochondria from Wistar rats were isolated after in vivo I/R with or without APoC (1.4%-vol isoflurane, 1 minimum alveolar concentration), and mitochondrial permeability transition pore (mPTP) opening, mitochondrial membrane potential (DeltaPsi(m)), and oxygen consumption were assessed. In isolated cardiomyocytes and isolated mitochondria I/R injury was produced in vitro, with or without APoC (0.5 mM isoflurane). Intracellular Ca(2+), pH(m), pH(i) and DeltaPsi(m) were monitored with SNARF-1, TMRE and fluo-4, respectively. Myocyte survival was assessed when APoC was induced at pH 7.4 and 7.8. In isolated mitochondria oxygen consumption and ATP synthesis were measured. KEY
RESULTS: In vivo APoC protected against mPTP opening, slowed mitochondrial respiration and depolarized mitochondria. APoC decreased the number of hypercontracted cardiomyocytes at pH 7.4, but not at pH 7.8. APoC attenuated intracellular Ca(2+) accumulation, maintained lower pH(m), and preserved DeltaPsi(m) during reoxygenation. Isoflurane did not affect the regulation of cytosolic pH. In mitochondria, APoC preserved ATP production rate and respiration. CONCLUSIONS AND IMPLICATIONS: At reperfusion, APoC inhibited mitochondrial respiration, depolarized mitochondria and acidified pH(m). These events may lead to inhibition of mPTP opening and, consequently, to preserved DeltaPsi(m) and ATP synthesis. This reduces intracellular Ca(2+) overload and cell death.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20423337      PMCID: PMC2874845          DOI: 10.1111/j.1476-5381.2010.00698.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein Kinase C-epsilon-mediated pathway.

Authors:  Danijel Pravdic; Filip Sedlic; Yasushi Mio; Nikolina Vladic; Martin Bienengraeber; Zeljko J Bosnjak
Journal:  Anesthesiology       Date:  2009-08       Impact factor: 7.892

2.  Guide to Receptors and Channels (GRAC), 4th Edition.

Authors: 
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

3.  Application of a new pH-sensitive fluoroprobe (carboxy-SNARF-1) for intracellular pH measurement in small, isolated cells.

Authors:  K J Buckler; R D Vaughan-Jones
Journal:  Pflugers Arch       Date:  1990-10       Impact factor: 3.657

Review 4.  The mitochondrial permeability transition pore and its role in cell death.

Authors:  M Crompton
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

5.  Halothane protects cardiomyocytes against reoxygenation-induced hypercontracture.

Authors:  B Siegmund; W Schlack; Y V Ladilov; C Balser; H M Piper
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

6.  Effects of mitochondrial uncouplers on intracellular calcium, pH and membrane potential in rat carotid body type I cells.

Authors:  K J Buckler; R D Vaughan-Jones
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

7.  Role of SR Ca2+-ATPase in contractile dysfunction of myocytes in tachycardia-induced heart failure.

Authors:  K Igarashi-Saito; H Tsutsui; S Yamamoto; M Takahashi; S Kinugawa; H Tagawa; M Usui; M Yamamoto; K Egashira; A Takeshita
Journal:  Am J Physiol       Date:  1998-07

8.  Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion.

Authors:  Hajime Kin; Zhi-Qing Zhao; He-Ying Sun; Ning-Ping Wang; Joel S Corvera; Michael E Halkos; Faraz Kerendi; Robert A Guyton; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2004-04-01       Impact factor: 10.787

9.  In vivo cardioprotection by S-nitroso-2-mercaptopropionyl glycine.

Authors:  Sergiy M Nadtochiy; Lindsay S Burwell; Christopher A Ingraham; Cody M Spencer; Alan E Friedman; Carl A Pinkert; Paul S Brookes
Journal:  J Mol Cell Cardiol       Date:  2009-02-03       Impact factor: 5.000

10.  Postconditioning inhibits mPTP opening independent of oxidative phosphorylation and membrane potential.

Authors:  Melanie Paillard; Ludovic Gomez; Lionel Augeul; Joseph Loufouat; Edward J Lesnefsky; Michel Ovize
Journal:  J Mol Cell Cardiol       Date:  2009-02-27       Impact factor: 5.000

View more
  22 in total

1.  Mitochondria as pharmacological targets.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  Isoflurane modulates cardiac mitochondrial bioenergetics by selectively attenuating respiratory complexes.

Authors:  Bhawana Agarwal; Ranjan K Dash; David F Stowe; Zeljko J Bosnjak; Amadou K S Camara
Journal:  Biochim Biophys Acta       Date:  2013-12-17

3.  Exogenous H2S reduces the acetylation levels of mitochondrial respiratory enzymes via regulating the NAD+-SIRT3 pathway in cardiac tissues of db/db mice.

Authors:  Yu Sun; Zongyan Teng; Xiaojiao Sun; Linxue Zhang; Jian Chen; Bingzhu Wang; Fangping Lu; Ning Liu; Miao Yu; Shuo Peng; Yan Wang; Dechao Zhao; Yajun Zhao; Huan Ren; Zhongyi Cheng; Shiyun Dong; Fanghao Lu; Weihua Zhang
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-06-11       Impact factor: 4.310

4.  Isoflurane differentially modulates mitochondrial reactive oxygen species production via forward versus reverse electron transport flow: implications for preconditioning.

Authors:  Naoyuki Hirata; Yon Hee Shim; Danijel Pravdic; Nicole L Lohr; Philip F Pratt; Dorothee Weihrauch; Judy R Kersten; David C Warltier; Zeljko J Bosnjak; Martin Bienengraeber
Journal:  Anesthesiology       Date:  2011-09       Impact factor: 7.892

5.  Effect of nitric oxide donors S-nitroso-N-acetyl-DL-penicillamine, spermine NONOate and propylamine propylamine NONOate on intracellular pH in cardiomyocytes.

Authors:  Danijel Pravdic; Nikolina Vladic; Ivan Cavar; Zeljko J Bosnjak
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-09       Impact factor: 2.557

6.  Enhanced charge-independent mitochondrial free Ca(2+) and attenuated ADP-induced NADH oxidation by isoflurane: Implications for cardioprotection.

Authors:  Bhawana Agarwal; Amadou K S Camara; David F Stowe; Zeljko J Bosnjak; Ranjan K Dash
Journal:  Biochim Biophys Acta       Date:  2011-12-02

7.  Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.

Authors:  Amadou K S Camara; Martin Bienengraeber; David F Stowe
Journal:  Front Physiol       Date:  2011-04-12       Impact factor: 4.566

8.  Activation of Akt and cardioprotection against reperfusion injury are maximal with only five minutes of sevoflurane postconditioning in isolated rat hearts.

Authors:  Yuan-yuan Yao; Man-hua Zhu; Feng-jiang Zhang; Chuan-yun Wen; Lei-lei Ma; Wen-na Wang; Can-can Wang; Xian-bao Liu; Li-na Yu; Ling-bo Qian; Jian-an Wang; Min Yan
Journal:  J Zhejiang Univ Sci B       Date:  2013-06       Impact factor: 3.066

9.  Complex I and ATP synthase mediate membrane depolarization and matrix acidification by isoflurane in mitochondria.

Authors:  Danijel Pravdic; Naoyuki Hirata; Lauren Barber; Filip Sedlic; Zeljko J Bosnjak; Martin Bienengraeber
Journal:  Eur J Pharmacol       Date:  2012-07-11       Impact factor: 4.432

10.  Substrate-dependent modulation of oxidative phosphorylation in isolated mitochondria following in vitro hypoxia and reoxygenation injury.

Authors:  Daisuke Maruyama; Naoyuki Hirata; Ryo Miyashita; Ryoichi Kawaguchi; Michiaki Yamakage
Journal:  Exp Clin Cardiol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.